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Abstract Noninvasive positive-pressure home ventilation (NIPPHV) improves arterial blood gases, dyspnea and
health-related qualityof life (HRQL) in patientswith restrictive thoracic diseases.Whether these changes persistduring
the follow-up remains unclear.The aim of this study was to investigate the long-term effects of NIPPHVupon dyspnea,
HRQL, lung function andhospitalizationratein 35 patientswithkyphoscoliosis and 27 individualswith severalneuromus-
culardisorders.So,wemeasureddyspnea,HRQL, lung function andnocturnaloxygensaturation (SaO2) before andafter
3, 6, 9,12 and 18 months after NIPPHV.Dyspnea was assessed with the Borg scale and HRQL was measured using the
Spanishvalidatedversionofthe SF-36 questionnaire.Thekyphoscoliosisgroup showedsignificantimprovementof PaCO2
and SaO2 at 3months andminordyspnea changes at 6months afterNIPPHVhadbeenstarted.Thesepatients also showed
improved health status in the following categories: ‘‘physical role’’and ‘‘emotional role’’at 3 months and in the categories
‘‘social functioning’’,‘‘vitality’’and‘‘mentalhealth’’at 6 months after NIPPHV; some ofthese changespersisted at 9,12 and18
months.Intheneuromusculargroup, a significant improvementof SaO2 wasobserved at 3months andthispersisted for
18months.ChangesofHRQLinthisgroupincludeda significantimprovementin‘‘physicalrole’’at 3months,‘‘emotionalrole’’
and‘‘social functioning’’at 6 months and‘‘physical functioning’’at 9months.Thehospitalizationrate decreased significantly
in all patients from amean annual admission rate of1.1 (1.4) before NIPPHV to 0.6 (1.1) after12 months of ventilatory sup-
port (Po0.005).We conclude that: (a) NIPPHVhad a higher impact on arterial blood gases, dyspnea and health-related
quality of life in patientswith kyphoscoliosis than in thosewith neuromuscular disorders; (b) most clinical and functional
changes persisted at long term and (c) a significant decrease in the hospitalization rate after NIPPHVoccurred in both
groups.r2002 Elsevier Science Ltd.Allrights reserved.
doi:10.1053/rmed.2002.1347, available online at http://www.idealibrary.comon
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Noninvasive positive-pressure home ventilation
(NIPPHV) hasbecomewidely available as a formof home
ventilatory support in conditions leading to alveolar
hypoventilation, mainly neuromuscular disorders and
chest wall diseases such as kyphoscoliosis (1,2). In these
patients, NIPPHV improves arterial blood gases, symp-
toms related to daytime hypercapnia and inspiratory
muscle endurance (3,4). The best results have been
observed in patients with kyphoscoliosis and other re-
strictive thoracic disease such as sequelae of tuberculo-Received 26 October 2001, accepted in revised form 20 February 2002
Correspondence shouldbe addressed to:DraDoloresNau¡al, Servicio
deNeumolog|¤a,Hospital Universitario La FeAvda.Campanar 21,46009
Valencia, Spain.Fax +34 96 3868789, +34-93-3987397;
E-mail: dneu¡al@separ.essis. In contrast, NIPPHV does not seem to modify lung
mechanics or respiratory muscle strength in patients
with neuromuscular diseases and the usefulness of
NIPPHVin stable chronic obstructivepulmonary disease
(COPD) is still controversial (5,6). Further, only a few
studies have evaluated the impact of NIPPHVon health-
related quality of life (HRQL).These studies generally re-
ported positive cross-sectional e¡ects of NIPPHVupon
both psychosocial functioning and mental well-being
(7^9). To date, however, none has evaluated HRQL
changes longitudinally.
Our study was designed to determine prospectively
the long-terme¡ects ofNIPPHVuponclinical symptoms,
HRQL, pulmonary function and nocturnal oxygen sa-
turation (SaO2) in two groups of patients with thoracic
restrictive disorders, namely those with kyphoscoliosis
and thosewith neuromuscular diseases.
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Patients
This was a prospective study of consecutive patients di-
agnosed of kyphoscoliosis or neuromuscular diseases be-
tween January 1997 and March 2000. All patients had
been referred to our department to evaluate the need
of NIPPHV because chronic hypoventilation occurred
due to either kyphoscoliosis or neuromuscular disease.
All of them showed a moderate-to-severe restrictive
ventilatory pattern and were clinically stable, as de¢ned
by the absence of lung infection or need of hospitaliza-
tion since 3 months prior to hospitalization. Informed
consentwas obtained from all of them.
Initial assessment
The initial evaluation included a complete medical his-
tory, assessment of dyspnea and HRQL, physical exami-
nation, routine laboratory tests, chest radiograph,
electrocardiography and pulmonary function test
(PFT). The latter included the determination of forced
spirometry, static lung volumes, maximal inspiratory
and expiratory pressures, arterial blood gases and noc-
turnal pulse-oximetry. Forced expiratory maneuvers
were recorded with a Collinss GII-Plus spirometer
(MA, U.S.A.) following the guidelines of the American
Thoracic Society (10). Pulmonary volumes were mea-
sured with a Collinss BO-XII pletysmograph. Predicted
valueswere those of the EuropeanCommunity (11).Max-
imal inspiratory pressure (MIP) wasmeasured at residual
volume and maximal expiratory pressure at total lung
capacity using an electromanometer (Siebelmed 163s,
Siebel, Barcelona, Spain) connected to a recorder (x^y
Servogor 731s, Goetz Metrawatt, Nuremberg, Ger-
many).The reference values were those of the Sociedad
Espan+ ola de Aparato Respiratorio (SEPAR) (12). Arterial
blood gases (ABL330s, Radiometer, Copenhagen, Den-
mark) were measured in blood samples drawn from the
radial artery by puncture, while the patient was breath-
ing air spontaneously.Nocturnal arterial oxygen satura-
tion (SaO2) was monitored continuously by pulse-
oximetry (Ohmeda Oximeter 3000s, CO,U.S.A.) using
a ¢nger probe. The baseline level of dyspnea was esti-
mated with the Borg scale, which ranged from 0 to 10
(13). The quality of life was evaluated at baseline using
the Spanish validated version of the SF-36 HRQL ques-
tionnaire (14). This generic instrument comprises 36
items grouped into eight categories: ‘‘physical function-
ing’’ (the extent towhich health interfereswith activities
such as bathing, walking, dressing, shopping, climbing
stairs); ‘‘physical role’’ and ‘‘emotional role’’ (the extent
to which health interferes with daily activities because
of physical or emotional problems); ‘‘bodily pain’’ (the ex-
tent of anypain over thepast 4weeks); ‘‘vitality’’ (subjec-tive energyor tiredness); ‘‘social functioning’’ (the extent
to which health interferes with social activities such as
visiting friends or relatives during the precedingmonth);
‘‘mental health’’ (asks about depression, anxiety and psy-
chologicalwell-being during thepastmonth); and‘‘gener-
al health’’ (as an overall rating of current health). The
patients indicate their current state by scoring each item
from 0 to100. Lower scores are related to increasing im-
pairment or severity of symptoms (14).
Noninvasive ventilation
According to the accepted guidelines (15), NIPPHV was
indicated if the patient showed dyspnea or morning
headache plus at least one of the following features:
forced vital capacity (FVC) o50% of predicted, MIP
o60 cm H2O, SaO2 o88% for 5 consecutive minutes
during nocturnal monitoring or PaCO2 445mmHg.
Thewere hospitalized in order to start NIPPHVand pa-
tients were instructed to use the ventilator at night dur-
ing a mean of 7h using a commercial nasal mask
(Sullivansor Adamss) and a bilevel pressure ventilation
system (DP90s, Taemas Paris, France) with a minimum
inspiratory and expiratory positive airway pressures of
10 and 4cm H2O, respectively. Both inspiratory and ex-
piratory pressures were adjusted to maximize the
change of arterial bloodgases.Nonetheless, oxygen sup-
plementation (2 l/min) was indicatedwhen PaO2was be-
low 55mmHg before NIPPHV. During hospitalization,
nocturnal pulse-oximetry and arterial blood gases were
performed every 24h.Once the patients were ¢tted to
NIPPHV, they were discharged. After discharge, during
the entire follow-up, technically skilled personnel super-
vised the installation of the equipment at home and the
compliance toNIPPHVwas assessedby aweekly reading
of the counter-built placed in the ventilator.
Study protocol
Patients were seen in the clinic every 3 months. Besides,
they had access to 24h telephone consultation. Arterial
blood gases, nocturnal pulse-oximetry, lung function,
dyspnea and HRQL were assessed at 3, 6, 9, 12 and 18
months after the onset of homeventilation.The hospita-
lization rate before and after NIPPHV were also re-
corded.
Statistical analysis
Results are presented as mean7SD. Baseline data were
compared between the two groups of patients using an
unpaired t-test andMann^WhitneyU test. An analysis of
variance, ANOVA, with Bonferroni’s correction was
used to assess the statistical signi¢cance of changes in
PFT, arterial blood gases, SaO2, MIP and dyspnea ob-
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ever variables were not normally distributed. E¡ect size
(ES) was used to assess the relevance of changes ob-
served in dyspnea andHRQL afterNIPPHV.Thiswas cal-
culated as ES = (m1 ^ m2)/s1, where m1 is the pre-
treatment mean, m2 the post-treatment mean, and s1
the pre-treatment standard deviation (16). It is generally
accepted that anES of 0.20 indicates a small e¡ect, one of
0.50 amoderate e¡ect, and one of 0.80 or greater a large
e¡ect (17). The Pearson product-moment correlation
coe⁄cient was calculated to determine the relationship
between PFT data, dyspnea and HRQL.The hospitaliza-
tion rates were compared using a paired t-test (95% CI).
The statistical signi¢cancewas set at Po0.05.The Statis-
tical Package for the Social Sciences (SPSS) 9.0 computer
programwas used for statistical analysis.
RESULTS
Patients characteristics
The initial groupwas constituted by 62 patients, 35 with
kyphoscoliosis (21men, mean age 52.9 (16.4) and 14 wo-
men mean age 60.5 (18.6) ) and 27 with di¡erent neuro-
muscular diseases (14 men, mean age 35.1 (19.6) and 13
women, mean age 50.5 (21.3) including amyotrophic lat-
eral sclerosis (ALS) (n=10), Duchenne’s dystrophy
(n=4), Steinert’s disease (n=4), spinal atrophy (n=2),
Werdnig^Ho¡man disease (n=2), myasthenia gravis
(n=2),Charcot^Marie ^Tooth disease (n=1),Friedreich’s
ataxia (n=1) and nemalinemyopathy (n=1).
Patients used the ventilators at a mean of 7h/night, as
it was assessed by checking the counterbilt.
Twenty-nine patients (47.6%) (19 with kyphoscoliosis
and 10 with neuromuscular diseases) required supple-
mentary oxygen.
Ten patients (8 with ALS and 2 with kyphoscoliosis)
died during the follow-up due to respiratory failure
(n=7) or community acquired pneumonia (n=3). Dead
patients were removed of the statistical analysis since
their death. The mean duration of the follow-up of the
remaining 52 patients was18 months.
Baseline data
The mean (SD) values of the di¡erent variables (FVC,
FEV1, TLC, SaO2, MIP, PaO2, PaCO2 and dyspnea mea-
suredby the Borg scale) determined at baseline and dur-
ing the follow-up in patients with kyphoscoliosis and
neuromuscular disorders are shown inTables1 and 2. At
baseline, the former showed lower SaO2 values andhigh-
er degree of dyspnea than the latter.Tables 3 and 4 show
the SF36 scores determined at baseline and during the
follow-up in the kyphoscoliotic and neuromuscular pa-
tients, respectively. At baseline, the scores of the ‘‘physi-
cal role’’, ‘‘emotional role’’, ‘‘vitality’’, ‘‘mental health’’ and‘‘general health’’ domains in patients with neuromuscular
diseases corresponded to the 5th and 25th percentile of
an age-matched reference Spanish population (17); ‘‘phy-
sical functioning’’was below the 5th percentile and‘‘bod-
ily pain’’ and ‘‘social functioning’’ between the 25th and
50th percentile.
E¡ects of NIPPHV
Patientswithkyphoscoliosis showed signi¢cant improve-
mentof nocturnal desaturation and daytime PCO2, from
months 3 until 18 during the follow-up (see Table 1).
Dyspnea decreased signi¢cantly (ES=1.30; Po0.05)
after 6 months of NIPPHV therapy and did not return
to the baseline in the follow-up. In neuromuscular
patients, we only observed signi¢cant improvement in
nocturnal SaO2 frommonth 3. Spirometry, lung volumes
and MIP did not change signi¢cantly during the follow-up
in any of the two groups. Actually, neuromuscular
patients showed a signi¢cant decrease of FVC and FEV1
atmonth12 (Table 2).
As can be seen in Table 3, NIPPHV improved signi¢-
cantly in the kyphoscoliotic group with the following
HRQL domains: ‘‘physical role’’ (ES=1.4, Po0.001), and
‘‘emotional role’’ (ES=1.26, Po0.002) at 3 months and
‘‘social functioning’’ (ES=1.12, Po0.003), ‘‘vitality’’
(ES=1.12, Po0.02) and ‘‘mental role’’ (ES=1.01, Po0.05)
at 6 months. Only the improvement of ‘‘physical role’’,
‘‘social functioning’’ and ‘‘emotional role’’ categories per-
sisted at18 months of NIHV. In patients with neuromus-
cular diseases, as can be seen in Table 4, NIPPHV
improved signi¢cantly: ‘‘physical role’’ (ES=0.95,
Po0.04) at 3 months; ‘‘social functioning’’ (ES=0.84,
Po0.05) at 6 months and ‘‘physical functioning’’
(ES=0.54,Po 0.05) at 9months.However, in this group,
the ‘‘physical role’’ and ‘‘emotional role’’ decreased at 12
and18 months vs the results at 6 months, but they were
still better than at baseline.We found a signi¢cant corre-
lation between the improvement of ‘‘physical function-
ing’’ and the changes of TLC (r=0.6, Po0.007) and
PCO2 (r=0.67,Po0.001) at 3 and 6months afterNIPPHV.
The hospitalization rate decreased signi¢cantly in all
patients: from 1.2 (1.8) in the kyphoscoliosis group and
1.1 (1.2) in the neuromuscular patients before NIPPHV to
0.8 (1.2) P=0.01and 0.3 (1.2) P=0.005, respectively, after
NIPPHV.
DISCUSSION
Our results allow us to conclude that NIPPHV improves
dyspnea, SaO2 and quality of life and reduces PaCO2 in
patients with kyphoscoliosis and that these changes per-
sisted for 18 months after the start of NIPPHV.On the
other hand, neuromuscular patients showed only an im-
provementon SaO2 andquality of life thatdisappeared in
TABLE 1. Mean (SD) valuesof lung function, nocturnaloxygendesaturation anddyspnea score atbaseline andafter 3,6,9,12 and
18 months of NIPPHVinpatientswithkyphoscoliosis
Baseline 3 months 6 months 9 months 12 months 18 months
Numberof patients 35 35 34 34 33 33
FVC, % predicted 42.2 (19) 44 (17.1) 46.3 (16.5) 43 (17.3) 44.1 (15.5) 4.5 (17.2)
FEV1, % predicted 37.5 (18.4) 36.3 (14.8) 36.4 (12.6) 34.5 (15.2) 34.1 (12.3) 34.7 (13.1)
TLC, l/min 63 (18.3) 5 7.1 (19.8) 56 (19.1) 52 (14.4) 52.5 (20.1) 56 (19)
SaO2o90% + 42 (36.7) 19.7 (25.8)* 23.1 (31.5)* 26.9 (31)* 18.8 (24.5)* 12.5 (27.4)*
MIP, %predicted 58 (17) 60 (17.1) 59.4 (11.6) 61.3 (13.7) 62.1 (17.3) 62.4 (18.1)
PaO2, mmHg 57.5 (8.1) 63.6 (8.6) 61.6 (9.2) 63.1 (9.6) 62.2 (11) 64.4 (10.8)
PaCO2, mmHg 56.8 (12.6) 49.3 (6.2)* 49 (6.8)* 49.7 (8.3)* 48.7 (5.9)* 46 (6.1)*
Borg scale 4.5 (2.1) 3. 5 (2.2) 3 (1.2) 3.4 (2.2) 3.8 (1.3) 3.1 (1.2)
aNight-time percentage of SaO2o90%.
*Po0.05 vsbaseline.
TABLE 2. Mean (SD) values of lung function, nocturnal oxygen desaturation and dyspnea score at baseline and after 3, 6,9,12
and18 months of NIPPHVinpatientswithneuromusculardisorders
Baseline 3 months 6 month 9 months 12 months 18 months
Numberof patients 27 25 24 21 19 19
FVC, % predicted 37.5 (20.3) 31.6 (18) 35.5 (18.4) 29.4 (16.6) 27.8 (21.6) 24 (15.2)
FEV1, % predicted 38.2 (21.2) 30.5 (16.4) 33.5 (15.6) 25.1 (19.6) 26.3 (19.5) 23.9 (14.1)
TLC, l/min 53 (21.7) 48.7 (2) 49 (18.3) 45.6 (18.5) 30.5 (16.2) 37.6 (15.4)
SaO2o90%a 26.8 (36) 11.7 (20.1)* 11.4 (21.3)* 7.8 (13.8)* 12 (29.4)* 7.1 (21)*
MIP, % predicted 41.5 (16.8) 41 (13.5) 43.8 (23.5) 42.1 (24.2) 39.1 (25.1) 35.1 (26.9)
PaO2, mmHg 70.6 (15.7) 68.2 (11.5) 67.7 (12.2) 68.7 (10.6) 72.8 (12.7) 73.8 (15.1)
PaCO2, mmHg 51.3 (11.9) 49.9 (10.4) 52.2 (11.9) 50.1 (6.9) 46.8 (8.4) 47 (9.2)
Borg scale 2.7 (1.9) 2.34 (1.8) 2.7 (1.5) 2.8 (1.2) 3.2 (2) 3.3 (3.1)
aNight-time percentage of SaO2o90%.
*Po0.05 versusbaseline.
TABLE 3. Mean (SD) scores obtained in the di¡erentdomains of SF-36 questionnaire at baseline and 3,6,9,12 and18 months of
NIPPHVinpatientswithkyphoscoliosis
Category Baseline 3 months 6 months 9 months 12 months 18 months
Physical functioning 33.1 (22.9) 44.2 (17.4) 47 (18.6) 43.6 (17.1) 48 (20.1) 46.4 (17.1)
Role physical 37.9 (42.3) 80 (34.3)* 90.2 (18.2)* 81.9 (32.9)* 77.7 (36.2)* 78.5 (37.7)*
Role emotional 40.6 (43.8) 79.8 (40)* 81.5 (33)* 85 (28.6)* 87.1 (28.3)* 79.6 (30.6)*
Bodilypain 72.1 (31) 75. (28) 83.2 (20.8) 85.7 (23.3) 89.5 (16.3) 82.8 (51.5)
Vitality 40.9 (25.1) 56.1 (22.3) 62 (17.7)* 60.5 (19.6)* 58.6 (21.8) 56.4 (26.3)
Social functioning 65.7 (35.1) 84 (28.6) 93.5 (15.9)* 94.4 (23.5)* 95.8 (17.8)* 92.7 (19)*
Mentalhealth 48.2 (25) 61.3 (22.8) 66.2 (21.7)* 70.4 (18)* 66 (20.3) 61.7 (15.1)
Generalhealth 43.3 (23.4) 47.3 (13.1) 48.7 (19) 52.3 (14) 47.9 (22) 45.8 (17)
*Po0.05 vsbaseline.
780 RESPIRATORYMEDICINEthe long-term follow-up; however, the hospitalization
rate decreased in the two groups.
NIPPHV has been shown to reverse nocturnal hypo-
ventilation and to improve daytime symptoms and gasexchange in patients with chronic respiratory failure
due to restrictive thoracic diseases (18^20). An increase
of MIP and respiratory muscle endurance after NIPPHV
has been reported by some (3,4,19,20) but not all investi-
TABLE 4. Mean (SD) scoresobtainedinthedi¡erentdomainsof SF-36 questionnaire atbaseline andafter 3,6,9,12 and18months
of NIPPHVinpatientswithneuromusculardiseases
Category Baseline 3 months 6 months 9 months 12 months 18 months
Physical functioning 11.4 (18) 9 (15.7) 8.6 (12) 4.5 (11)* 2.3 (12)* 1.25 (12.5)*
Role physical 35.7 (37.6) 61 (75.8)* 81.2 (33.7)* 75 (37.2)* 50 (50) 50 (57.7)
Role emotional 55.3 (46.6) 56 (44.5) 67.2 (23.1) 57.2 (10) 49.3 (12.1) 43.7 (24.1)
Bodilypain 66.2 (37.2) 85.7 (27.2) 74.0 (29.4) 80.3 (26) 49.3 (12.1) 57.2 (41.2)
Vitality 42.1 (20.1) 47.5 (14.3) 52.7 (13.1) 49.5 (18.7) 43.5 (20.7) 33.7 (7.5)
Social functioning 66.9 (36.2) 76.2 (16.6) 88.5 (22.8)* 95 (10.5)* 73.1 (38.5) 62.5 (47.8)
Mentalhealth 59.1 (25.6) 68 (21.4) 65.1 (18.3) 65.2 (17.8) 61.1 (19.1) 63 (18.8)
Generalhealth 38.7 (24) 32.9 (15) 33.7 (17.2) 31.4 (19.8) 32.2 (21.2) 28.7 (14.3)
*Po0.05 vsbaseline.
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(whichmayreset the sensitivityof therespiratory center
to hypercapnia (23), a more e⁄cient alveolar ventilation
because a reduction of dead space ventilation (VD/VT)
and/or a reduced work of breathing may explain why
NIPPHV improves gas exchange without modifying any
spirometric index (5,24,25). In our study, the changes in
PaCO2 canbe attributed toNIPPHV because all patients
had received conventional medical treatment before
NIPPHV unsuccessfully. Likewise, we attribute the im-
provement in nocturnal oxygenation toNIPPHVbecause
these patients were also treated previously with oxygen
therapy unsuccessfully. In keeping with the previous stu-
dies, we observed that NIPPHVdid notmodify spirome-
try, lung volumes or MIP during the follow-up. The
deterioration of lung function found in the neuromuscu-
lar group at12 months is likely to be due to the progres-
sive clinical course of these neuromuscular diseases.
The e¡ect of NIPPHVon dyspnea has been evaluated
before. It is believed that the decrease of dyspnea
through the mechanism of NIPPHV is somehow related
to the improvement of gas exchange and not to changes
of spirometry or lung volumes (8).We observed in the
present study, in keeping with this interpretation, that
NIPPHV improved dyspnea and that this e¡ect was
related to the decrease of nocturnal desaturation in
patients with kyphoscoliosis who, as discussed before,
did not show any signi¢cant change in lung function.
On the other hand, NIPPHV did not improve dyspnea
nor arterial oxygenation in patients with neuromuscular
disorders.
Several previous papers have alreadyevaluated the im-
pactofNIPPHVuponHRQL.For instance, in1994, Pehrs-
son et al. used the Sickness Impact Pro¢le (SIP)
questionnaire complemented with the Mood Adjective
Check List (MACL) to assess the e¡ects of NIPPHV in
patients with restrictive thoracic diseases and reported
that, despite the presence of severe physical limitations,
those patients showed good ‘‘psychosocial functioning’’,
as comparedwith a reference population, and concluded
that the quality of life was mainly determined by theirmental state (8). Simmonds and Elliot used the SF36
questionnaire to analyze the outcome of a large group
of restrictive and obstructive patients under NIPPHV
and found that ‘‘physical functioning’’ was signi¢cantly
higher in patientswith kyphoscoliosis, sequelae of tuber-
culosis and poliomyelitis than in the COPD group (7).
These authors, however, did not report the timing of
HRQL changes nor investigated potential correlations
between the latter and variations of arterial blood gases
or dyspnea scores. More recently, Simmonds et al. used
the same questionnaire to evaluate health perception
and social aspects of quality of life in di¡erent neuromus-
cular patients treated with NIPPHV and reported that
the response of Duchenne’s patients was similar to that
of other neuromuscular diseases (26).None of these stu-
dies, however, has compared HRQL scores before and
after startingNIPPHVnor has evaluated the time course
of HRQL changes during the follow-up.
Our study, on the contrary, was speci¢cally designed
for this purpose. We found that the quality of life im-
proved signi¢cantly particularly in the kyphoscoliotic
group.Thesepatients showedclear changes in their‘‘phy-
sical role’’ and ‘‘emotional role’’domains early after start-
ing NIPPHV; changes of ‘‘mental role’’,‘‘vitality’’or ‘‘social
functioning’’ appeared later. We believe that these
changes of ‘‘physical role’’ and ‘‘vitality’’ are likely to be
related to the improvement of arterial blood gases bea-
cuse the lungmechanics did not change signi¢cantly. Be-
sides, as the improvement of dyspnea, PaCO2 and SaO2
persisted 18 months after NIPPHV, the changes in
HRQL persisted also in this group of patients in the
long-term follow-up. In neuromuscular patients, the im-
provement of ‘‘physical functioning’’ was the only change
that persisted at 18 months of NIPPHV, since ‘‘physical
role’’ and ‘‘emotional role’’ that were improving up to
the 9th month worsened thereafter. The deterioration
in these patients was parallel to the decline of FVC and
FEV1observed in these patients.
Baseline di¡erences in SF36 scores between patients
with kyphoscoliosis and those with neuromuscular dis-
eases, as well as the heterogeneity and natural history
782 RESPIRATORYMEDICINEof the latterFALS particularlyFmight have contribu-
ted to the di¡erent results observed in the two groups
of patients studied here. In most patients with ALS,
NIPPHVwas started at an advanced stage of the disease
and almost all of themdied during the follow-up.The im-
pact of NIPPHVonALS is controversial.Moss et al. found
that only 10% of the ALS patients were happy under
NIPPHVand the vastmajority of thempreferred to stop
it (27). In contrast, Bach supported theuse ofNIPPHVin
these patients, because tracheostomy was delayed or
avoided in most individuals included in his series (28).
The e¡ect of NIPPHVon the prognosis of ALS has been
generally disappointing but, perhaps, a greater survival
can be achievedwhen NIPPHV is started early after the
diagnosis (28).
Finally, the impact of NIPPHV on the hospitalization
ratewas similar to that reported in the previous studies
(9).Webelieve that this importantreduction observed in
thewhole group can also contribute to thebetterHRQL
after NIPPHV.
Two potential limitations of our study deserve com-
ment. First, our study lacks a control group.However, it
seems that denial of NIPPHV to patients with hypoventi-
lation secondary to severe restrictive disorders would
be probably unethical. Second, we studied a relatively
small number of patients .Yet, this is similar to the other
series previously published and, besides, the follow-up is
longer than in other groups.
We conclude that the impact of NIPPHV is higher in
patients with kyphoscoliosis than in neuromuscular dis-
orders and also that these e¡ects upon gas exchange,
dyspnea and quality of life persist for a long term in the
former group. Thus, these results support the use of
NIPPHV in patients with kyphoscoliosis .The scenario is
slightly di¡erent for patients with neuromuscular dis-
eases, although some of them may also bene¢t from
NIPPHV.
However, we think that the overall reduction of the
hospitalization rate justi¢es the use of NIPPHV in most
of the patients with restrictive thoracic diseases.
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